fbpx
Want to save 25%? Check out our subscriptions!

Evaluating the Effectiveness of New Biologics in Hidradenitis Suppurativa

The landscape of Hidradenitis Suppurativa (HS) treatment is continually evolving, with new biologics emerging as potential game-changers for patients who have not responded to conventional therapies. This blog explores some of the latest biologics under investigation, their success rates, and the studies that support their use in managing HS.

Bimekizumab:

Bimekizumab is a dual inhibitor of interleukin-17A (IL-17A) and interleukin-17F (IL-17F). It was initially developed for the treatment of moderate to severe plaque psoriasis and is now being explored for its potential in treating HS.

  • Key Studies: A Phase 2 study conducted by Schellenberg et al. in 2022 aimed to evaluate the safety and efficacy of Bimekizumab in patients with moderate to severe HS. In this study, patients were randomized to receive either Bimekizumab or a placebo. The results were promising, with 50% of patients treated with Bimekizumab achieving a 50% reduction in abscess and inflammatory nodule count, compared to 20% in the placebo group.
  • Concusion: Bimekizumab shows promise as a treatment for HS, particularly in reducing the number of abscesses and inflammatory nodules. While these early results are encouraging, ongoing Phase 3 trials will provide more comprehensive data on its efficacy and safety.

Guselkumab (Tremfya):

Guselkumab is an interleukin-23 (IL-23) inhibitor, originally developed for the treatment of moderate to severe plaque psoriasis. It has also been approved for psoriatic arthritis.

  • Role in HS: Guselkumab’s potential in treating HS was explored in a Phase 2 study conducted by Ederaine et al. in 2022. The study included 36 patients with moderate to severe HS who were randomized to receive either Guselkumab or a placebo. The results showed that 54
  • Key Studies: Guselkumab’s potential in treating HS was explored in a Phase 2 study conducted by Ederaine et al. in 2022. The study included 36 patients with moderate to severe HS who were randomized to receive either Guselkumab or a placebo. The results showed that 54% of patients treated with Guselkumab achieved HiSCR (Hidradenitis Suppurativa Clinical Response) at Week 16, compared to 26% in the placebo group. This significant improvement highlights Guselkumab’s potential as a therapeutic option for HS.
  • Conclusion: Guselkumab has demonstrated efficacy in reducing HS symptoms, with a success rate of 54% in Phase 2 trials. As more data becomes available from ongoing and future studies, Guselkumab may become a valuable addition to the HS treatment arsenal, particularly for patients who have not found relief with other therapies.

Brodalumab (Siliq):

Brodalumab is an interleukin-17 receptor A (IL-17RA) antagonist, initially developed for the treatment of moderate to severe plaque psoriasis. Its mechanism of action involves blocking the IL-17 receptor, which plays a role in the inflammatory processes associated with autoimmune conditions like psoriasis and HS.

  • Key Studies: In a Phase 2 open-label study conducted by Kolkman et al. in 2022, the efficacy of Brodalumab was assessed in 10 patients with moderate to severe HS. The results indicated that 50% of the patients showed partial responses, including reductions in inflammatory nodules and abscesses. Although the study had a small sample size, the findings provide preliminary evidence of Brodalumab’s potential in treating HS.
  • Conclusion: Brodalumab shows promise as a treatment option for HS, particularly for patients who do not respond to other biologics. However, given the small scale of current studies, further research is needed to confirm its efficacy and safety. If larger trials replicate these results, Brodalumab could become an important therapy for HS management.

Methotrexate:

Original Design Purpose: Methotrexate is an antimetabolite and antifolate drug initially developed as a chemotherapy agent for cancer treatment. Over time, it was discovered to have potent immunosuppressive properties, leading to its widespread use in treating autoimmune conditions such as rheumatoid arthritis and psoriasis.

  • Role in HS: Methotrexate is used off-label for HS, particularly in cases where patients have not responded to conventional therapies or biologics. Its use in HS is generally based on its anti-inflammatory properties and its role in modulating immune responses.
  • Key Studies: In a small cohort study conducted by Micheletti et al. in 2011, 10 HS patients were treated with low-dose Methotrexate (15 mg/week). The results showed that 60% of the patients experienced improvement in their symptoms, including reductions in nodule count and abscess formation. Additionally, a case report by Jansen et al. in 2017 described a 35-year-old woman with severe HS who showed significant improvement in her symptoms over six months of Methotrexate treatment.
  • Conclusion: Methotrexate may benefit some HS patients, particularly those with milder disease or as an adjunct to other therapies. Although it is not a first-line treatment, Methotrexate offers a potential option for patients who have exhausted other avenues. However, it is important to note that Methotrexate’s effectiveness in HS has not been extensively studied, and its use should be carefully considered by healthcare providers.

Orencia (Abatacept):

Abatacept is a selective co-stimulation modulator developed for the treatment of rheumatoid arthritis. It was later approved for juvenile idiopathic arthritis and psoriatic arthritis. Abatacept works by inhibiting the activation of T-cells, which play a crucial role in the immune response, thereby reducing inflammation.

  • Role in HS: Abatacept has been explored as an off-label treatment for HS due to its ability to modulate the immune system, particularly in cases where HS is thought to be driven by T-cell-mediated inflammation.
  • Key Studies: In a case series conducted by Garg et al. in 2019, three patients with severe HS were treated with Abatacept. The results were mixed, with two patients showing significant improvement and one experiencing a partial response. The treatment was well-tolerated, with no significant adverse effects reported. Although the data is limited, these findings suggest that Abatacept may be effective for certain patients with HS, particularly those with immune-mediated disease features.
  • Conclusion: Abatacept may offer hope for patients with HS who have not responded to other treatments, especially in cases where immune modulation is required. However, due to limited evidence, its use in HS is not widespread, and further research is needed to establish its efficacy.

Rituxan (Rituximab):

Rituximab is a monoclonal antibody targeting CD20, a protein found on the surface of B-cells. It was initially developed for the treatment of B-cell non-Hodgkin lymphoma and later approved for rheumatoid arthritis, chronic lymphocytic leukemia, and certain autoimmune diseases.

  • Role in HS: Rituximab has been investigated as an off-label treatment for HS, especially in patients where B-cell-mediated autoimmunity is suspected. By depleting B-cells, Rituximab reduces inflammation and could potentially alleviate HS symptoms.
  • Key Studies: A case report by Khandpur et al. in 2014 described a 42-year-old woman with severe HS who experienced significant improvement after two courses of Rituximab. The patient had a reduction in the number of abscesses and inflammatory nodules. Although there are currently no large-scale clinical trials assessing Rituximab specifically for HS, the case report suggests that it may benefit some patients, particularly those with underlying autoimmune components.
  • Conclusion: Rituximab may be a viable option for HS patients with an autoimmune component, although its use is limited due to a lack of robust evidence. Healthcare providers considering Rituximab for HS should weigh the potential benefits against the risks, and more research is needed to better understand its role in HS treatment.

Xeljanz (Tofacitinib):

Tofacitinib is a Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis. It has also been approved for psoriatic arthritis and ulcerative colitis. Tofacitinib works by inhibiting JAK enzymes, which are involved in the signaling pathways that lead to the production of inflammatory cytokines. By blocking these pathways, Tofacitinib reduces inflammation and immune responses.

  • Role in HS: Tofacitinib is being explored as an off-label treatment for HS due to its potent anti-inflammatory properties and its ability to inhibit cytokine signaling.
  • Key Studies: A case report by Wagle et al. in 2018 described a 28-year-old woman with severe HS who achieved significant improvement after six months of treatment with Tofacitinib. The patient reported a decrease in the number of abscesses and a reduction in pain. Additionally, a small retrospective study by Jfri et al. in 2021 included 10 HS patients treated with Tofacitinib. The study found that 70% of the patients achieved at least partial remission, with a significant reduction in inflammatory lesions.
  • Conclusion: Tofacitinib shows promise as a treatment for HS, particularly in cases where TNF inhibitors are not effective. Its success rate of 70% in small studies suggests that it may be a valuable option for patients with refractory HS. However, further research is needed to confirm its long-term efficacy and safety.

 

The field of biologics for Hidradenitis Suppurativa treatment continues to evolve, with new and emerging therapies offering hope to patients who have struggled with conventional treatments. Bimekizumab, Guselkumab, Brodalumab, and other biologics show varying degrees of success in managing HS symptoms, and ongoing research will help to better define their roles in treatment. As these therapies undergo further testing and approval processes, they may become essential components of a comprehensive HS treatment strategy. For now, patients and healthcare providers should remain informed about these options and consider them when conventional therapies prove insufficient.

Join our HS Healers Facebook Group!

Useful Link

About

Products

Contact

Resources

Blog

FAQ

Refund and Returns Policy

Get in Touch

Facebook Twitter Instagram Pinterest Youtube Linkedin

© 2024, Amazing Ointments, All Rights Reserved